丙型肝炎病毒抑制剂达拉他韦中国专利申请情况解析

Analysis of patent applications of the HCV inhibitor daclatasvir in China

达拉他韦是百时美施贵宝公司研发的一种丙型肝炎病毒NS5A蛋白抑制剂。本文通过专利文献检索,对达拉他韦相关的中国专利申请情况进行了分析,重点解析原研公司百时美施贵宝在中国的专利布局,旨在为国内药物研发机构和制药企业在达拉他韦的后期开发、专利保护策略以及知识产权布局等方面提供有益的参考。

Daclatasvir is a medication used to treat hepatitis C. It stops hepatitis C virus（ HCV） viral RNA replication and protein translation by directly inhibiting HCV protein NS5 A. In this paper,we analyzed the patent applications of daclatasvir in China,mainly focusing on the time distribution and legal status of the patent applications of Bristol-Myers Squibb,as well as other applications related to daclatasvir. This paper may provide some beneficial suggestions in terms of drug research and development and protection of patents to domestic medicine research institutions and pharmaceutical companies.